A new treatment for Osteopenia, the rare but fatal condition that can cause bone loss in women, has been developed by researchers at the University of Pennsylvania and Stanford University.
The study, published in the American Journal of Obstetrics and Gynecology, says the treatment can be administered using a simple, non-invasive, pill that is available over-the-counter and can be taken with a simple daily medication.
Researchers say the treatment works by changing the way the body works.
“What’s so exciting is that this pill doesn’t need to be taken every day.
It’s very inexpensive, and the cost is really low,” Dr. Jessica Kast, an endometriologist at the Johns Hopkins University School of Medicine and the lead author of the study, told Newsweek.
“It’s very safe, and it’s really inexpensive, too.”
“We’re excited to be able to say that it’s the first pill that’s going to do this.
It has some important features that make it different from the other pills out there.”
The researchers say the new treatment works to reduce the risk of Osteopyrotein E (OEPE), a protein found in bone that can lead to bone loss.
In the study published in Clinical Endocrinology & Metabolism, Kast and her colleagues evaluated a pill made by Pfizer called TK-1 that had previously been tested in animals.
The pill is made with a compound called neomycin, which can slow down OEPE, which is produced by osteocytes and helps the body to produce new bone.
When the osteocytes make more bone, osteoblasts are released from the body, forming new bone tissue.
Researchers in the study used the pill in a rat model, where they injected the drug into the animals’ ovaries.
After 24 days, the mice were injected with either neomycin or the pill containing a mixture of neomycillin and the hormone estrogen.
The scientists observed a dramatic reduction in the amount of osteoporotic cells in the ovaries of the rats.
The researchers also found that the hormone estradiol, which was present in the pill, made a positive impact on the levels of osteoblastic cells, or osteoclasts.
The results were very encouraging.
“There were actually significant reductions in osteoporsome mass in the rat ovaries after estrogen treatment, which indicates that estrogen acts as an inhibitor of osteoclastic differentiation,” Kast said.
“This is a really exciting finding that we hope will help us develop a pill that will slow down osteoporenosis.”
The drug was tested in a separate study in humans, and when it was given to women, the researchers observed that it helped reduce the number of OEPEs in the pelvic floor muscles of women.
Kast’s team believes that the new pill could be an effective treatment for endometrial osteopores.
“The pill that we’ve developed works to help decrease the formation of OE, and that could be important for a lot of women who have endometria,” she said.
Kest is hopeful that the pill will be available soon, because the drug has already been approved by the Food and Drug Administration for use in women.
She said that Pfizer hopes that this new pill will eventually be tested in humans.
Kaste is optimistic that the drug will work, but said that the treatment could have serious side effects, like a possible increase in bleeding.
“Our concern is that there may be some side effects that could result in bleeding, so we’d like to get this drug approved by a doctor before we move it onto humans,” she told Newsweek in an interview.
The research is part of a growing body of research that has shown that many women are experiencing OE symptoms, and have little to no control over the condition.
KAST is working with other researchers to develop a drug that is safe and effective in women and will be approved in the near future.
“We are very excited to see this drug being approved,” she added.
KEST is working to develop the drug to treat OE in women as well as men.
“For women, this is really exciting,” Kest said.
She says the pill can also be used to treat women who are overweight or obese.
KASTER: If we can get this pill into the clinic, it could be a huge difference.
This is a major breakthrough.
We are working with our partners to get it approved.
We’ve been looking for the best way to get to the clinic and now it’s a matter of getting this pill to people.
KASS: I hope that by the time that we get the pill approved, this pill will work in women at least, and then it could have a huge impact on women.
It is a very important drug, and this is one of the best drugs out